GeoffreyTGibneyMD

Clinical Trials

• Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma Start of enrollment: 2010 Aug 13

  Completed

  Phase 1

• Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma Start of enrollment: 2012 Jul 27

  Completed

  Phase 1

• Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma Start of enrollment: 2012 Aug 03

  Active, not recruiting

  Phase 2

• Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts Start of enrollment: 2012 Oct 09

  Active, not recruiting

  Not Applicable

• Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor Start of enrollment: 2012 Dec 01

  Completed

  Phase 1

• A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma Start of enrollment: 2013 Jun 01

  Completed

  Phase 1, Phase 2

• Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064) Start of enrollment: 2013 Apr 30

  Completed

  Phase 2

• Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma Start of enrollment: 2013 Oct 23

  Completed

  Phase 2

• RTA 408 in the Treatment of Advanced Solid Tumors (NSCLC & Melanoma) - DISCOVER Start of enrollment: 2013 Dec 31

  Completed

  Phase 1

• Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma Start of enrollment: 2014 Jan 07

  Completed

  Phase 1

• Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Start of enrollment: 2014 May 29

  Active, not recruiting

  Phase 1

• Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma Start of enrollment: 2014 Aug 12

  Completed

  Phase 2

• Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma Start of enrollment: 2020 Mar 02

  Suspended

  Phase 2

• Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial Start of enrollment: 2021 Feb 09

  Recruiting

  Phase 2

• An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) Start of enrollment: 2019 Jul 18

  Recruiting

  Phase 2

  Roles: Contact

• Join now to see all